37 Results for "

RANKL-induced osteoclasts

" in MedChemExpress (MCE) Product Catalog:
Products (37)

37 Results for "RANKL-induced osteoclasts" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-B1246
CAS No.: 553-08-2
Target:  

Bacterial Proton Pump

Research Areas:  

Infection

Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N0259
CAS No.: 110623-73-9
Synonyms: Epmedin B
Epimedin B (Epmedin B) is a flavonoid active component found in Epimedium, with oral activity, and exhibits anti-osteoporotic and neuroprotective effects. Epimedin B inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and mature osteoclast bone resorption, inhibits the phosphorylation of JNK, p38 MAPK, PI3K, and AKT, activates the AMPK-Nrf2 antioxidant pathway, and reduces cellular and mitochondrial ROS. Epimedin B acts on ESR1 and exerts its effects via GPER. Epimedin B alleviates bone loss and improves bone microstructure in vivo, and in Parkinson's models protects dopaminergic neurons and maintains striatal dopamine levels through anti-apoptotic and anti-endoplasmic reticulum stress effects. Epimedin B can be used for research related to osteoporosis, diabetic osteoporosis, and Parkinson's disease .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-147369
CAS No.: 1912422-56-0
Purity:  99.97%
Research Areas:  

Others

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16782
CAS No.: 945614-12-0
Synonyms: ARRY-614
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W008634
CAS No.: 56741-95-8
Synonyms: U-54461; U-54461S; PNU-54461
Research Areas:  

Cancer

Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2736
CAS No.: 2150-11-0
3′,4′,7-Trihydroxyflavone is an orally active inhibitor of OXA-48 (IC50 = 1.89 μM) and COX-1 (IC50 = 36.37 μM). 3′,4′,7-Trihydroxyflavone exhibits antioxidant and anti-inflammatory properties, inhibiting the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α. 3′,4′,7-Trihydroxyflavone inhibits H2O2-induced neuronal apoptosis and ROS accumulation, and exerts anti-neuroinflammatory effects by suppressing the JNK-STAT1 pathway. 3′,4′,7-Trihydroxyflavone exhibits antimicrobial and antibiotic-modifying activities against multidrug-resistant Gram-negative enteric bacteria. 3′,4′,7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1. 3′,4′,7-Trihydroxyflavone activates the CREB-BDNF axis and restores scopolamine (HY-N0296)-induced memory deficits in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0805A
CAS No.: 18649-93-9
Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer .
loading...
    loading...
Cat. No.: HY-N5048
CAS No.: 122965-41-7
Synonyms: 6'-O-Galloyl paeoniflorin
Galloylpaeoniflorin (6'-O-Galloyl paeoniflorin) is an orally active galloylated derivative of Paeoniflorin (HY-N0293) found in peony roots with various anti-inflammatory and antioxidant activities. Galloylpaeoniflorin suppresses RANKL-induced activation of ERK, JNK, c-Fos, c-Jun, and NFATc1, and reduces osteoclast-specific gene expression. Galloylpaeoniflorin activates Nrf2 and PI3K/Akt pathways, inhibits NF-κB activation, and scavenges ROS to reduce oxidative DNA, lipid, and protein damage. Galloylpaeoniflorin attenuates neuroinflammation, inhibits apoptosis, reduces Helicobacter pylori-induced gastric mucosa injury and UVB-induced cell damage. Galloylpaeoniflorin can be used for the research of osteoporosis, gastritis, ischemic stroke and skin diseases .
loading...
    loading...
Cat. No.: HY-111083
CAS No.: 931695-79-3
Purity:  99.65%
Synonyms: CID23612552
Target:  

GPR55 PERK PKC ERK p38 MAPK

Research Areas:  

Metabolic Disease Cancer

ML191 (CID23612552) is a GPR55 antagonist. ML191 inhibits ERK phosphorylation and PKC β II translocation downstream of GPR55 signaling. ML191 suppresses LPI-induced activation of ERK1/2 and p38 MAPK signaling, blocks the transcription of RANKL-induced osteoclastogenesis markers, and reduces the bone resorption activity of mature osteoclasts promoted by RANKL. ML191 can be used to investigate diseases associated with bone degradation caused by excessive osteoclast activation, such as osteoporosis and bone damage during the formation stage of bone metastases .
loading...
    loading...
Cat. No.: HY-N10117
CAS No.: 138250-72-3
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
loading...
    loading...
Cat. No.: HY-168336
CAS No.: 2909474-29-7
Target:  

PPAR

Research Areas:  

Metabolic Disease

E0924G is an orally active activator for PPARδ with EC50 of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .
loading...
    loading...
Cat. No.: HY-N0943
CAS No.: 24808-04-6
(−)-Epiafzelechin is a COX-1 inhibitor with an IC50 of approximately 15 μM against COX-1 activity. (−)-Epiafzelechin also exhibits DPPH free radical scavenging activity, with an EC50 of 20.9 μM. (−)-Epiafzelechin promotes osteoblast differentiation by increasing ALP activity, ECM collagen content and Runx2 expression, while reducing the growth of osteoclast precursors and RANKL-induced TRAP activity, thereby regulating the bone remodeling process. (−)-Epiafzelechin alleviates ovariectomy-induced bone loss. (−)-Epiafzelechin can be used in studies related to bone remodeling, postmenopausal osteoporosis, inflammatory responses and oxidative stress .
loading...
    loading...
Cat. No.: HY-118482
CAS No.: 128533-02-8
Synonyms: Saurolactam
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .
loading...
    loading...
Cat. No.: HY-134314
CAS No.: 913645-39-3
8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice .
loading...
    loading...
Cat. No.: HY-121282B
CAS No.: 24360-97-2
Synonyms: Pecazine acetate
Target:  

Apoptosis MALT1

Research Areas:  

Others

Mepazine acetate (Pecazine acetate) is a drug that has the activity to inhibit the protease activity of MALT1. Mepazine acetate is often used to study the role of MALT1 in biology. Treatment of mouse bone marrow precursor cells with mepazine acetate strongly inhibited RANK ligand (RANKL)-induced osteoclast formation. Mepazine acetate also inhibited the expression of multiple osteoclast markers such as TRAP, feline hepsin K, and calcitonin. The protective effect of mepazine acetate was not affected by MALT1 deficiency. The mechanism of action of mepazine acetate may involve MALT1-independent mechanisms, and this aspect needs to be considered in future studies .
loading...
    loading...
Cat. No.: HY-N10076
CAS No.: 1191255-15-8
Ganomycin I is a non-competitive dual inhibitor of α-glucosidase and HMG-CoA reductase, with IC50 values of 0.3 μM and 12.3 μM, respectively. Ganomycin I inhibits HIV-1 protease, with an IC50 of 7.5 μg/mL. Ganomycin I also suppresses RANKL-induced osteoclast differentiation and bone resorption by inhibiting the activation of ERK, JNK and p38 MAPK, as well as downregulating the c-Fos/NFATc1 signaling pathway. Ganomycin I exhibits antibacterial activity against Gram-positive bacteria, and shows weak activity against Mycobacterium tuberculosis H37Ra. It can be used in research related to metabolic diseases, bone metabolism and anti-infection .
loading...
    loading...
Cat. No.: HY-N10062
CAS No.: 2923661-84-9
Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC50 value of 10.5 μM in RAW264.7 cells.
loading...
    loading...
Cat. No.: HY-153675
CAS No.: 547731-67-9
Purity:  98.51%
Target:  

PIN1

Research Areas:  

Metabolic Disease

BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research .
loading...
    loading...
Cat. No.: HY-N11775
CAS No.: 1934299-51-0
Synonyms: Plebeiolide D
Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating RANKL-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .
loading...
    loading...
Cat. No.: HY-N12507
CAS No.: 2968309-12-6
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .
loading...
    loading...